INSULINVORMGEMISCHFORMULIERUNG

European patent · EP3965802 · In force

Register entry

Publication number
EP3965802
Application number
EP20729312
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
May 4, 2020
Published
Mar 16, 2022
Granted
Jul 29, 2026
Protection ends at the latest
May 3, 2040
Next annual fee due
May 31, 2027
IPC classes
A61K 38/28 (2006.01)
A61K 47/02 (2006.01)
Priority
US 201962843881 P 06.05.2019
US 201962862573 P 17.06.2019
PCT application
PCT/US2020/031322 04.05.2020
PCT publication
WO2020/227214 12.11.2020
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Sep 24, 2026

    Agent entered

    Representative
    Kirker & Cie SA, Rue de Genève 122, CP 153, 1226 Genève-Thônex

    Published in Swissreg on 24.09.2026

  2. Jul 29, 2026

    Granted

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 29.07.2026

Parties

Holder

Baxter International Inc.

One Baxter Parkway, Deerfield, IL 60015, US

Baxter Healthcare SA

BAXTER HEALTHCARE SA

Thurgauerstrasse 130, 8152 Glattpark (Opfikon)

Agent

Kirker & Cie SA

Rue de Genève 122 CP 153, 1226 Genève-Thônex

Inventor

WONG, Joseph Chung Tak

Deerfield, Illinois 60015, US

LEE, Sarah Elizabeth

Deerfield, Illinois 60015, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.